Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer

Treatment with abiraterone acetate and prednisone (AA/P) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients. We evaluated the genetic variation in CYP17A1 as predictive of response to AA/P. A prospective collection of germline DNA prior to AA/P initiation and follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Binder, Moritz, Zhang, Ben Y., Hillman, David W., Kohli, Rhea, Kohli, Tanvi, Lee, Adam, Kohli, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964473/
https://www.ncbi.nlm.nih.gov/pubmed/27409606
http://dx.doi.org/10.3390/ijms17071097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964473/
https://www.ncbi.nlm.nih.gov/pubmed/27409606
http://dx.doi.org/10.3390/ijms17071097

Ejemplares similares